Ideaya Biosciences reports Phase 2 data for MAT2A inhibitor IDE397

Fresh Phase 2 data are adding weight to Ideaya Biosciences’ case for a targeted therapy it believes could be a first-in-class treatment option for certain types of urothelial cancer and lung cancer.

In a study with 18 evaluable patients, Ideaya’s drug helped seven of them shrink their tumors — translating to an overall response rate of 39%, including one complete response. Factoring in the 10 patients who achieved stable disease, Ideaya said the disease control rate comes in at 94%.

The data update comes almost two years after GSK passed on an option to license that drug, IDE397, and related compounds. While the Phase 2 study looked at monotherapy, it’s also being tested in combination with drugs from Amgen and Gilead — and the new results offer “important clinical proof-of-concept,” Ideaya CEO Yujiro Hata said in a press release.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks